Price (delayed)
$3.81
Market cap
$220.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.35
Enterprise value
$663.01M
Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous
There are no recent dividends present for OMER.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.